Date:	--/--/-- --:--:--
Event Id:	E5D8C4A7E
Action Type:	ACQUISITION
Action Status:	ANNOUNCED
Acquirer Symbol:
Target Symbol:	SWTX
Updated:	--/--/-- --:--:--
Purchase Price Per Share:	47
Price Per Share Currency:	USD
News References:	https://www.businesswire.com/news/home/20250427077657/en/

Action Notes

Merck KGaA, Darmstadt, Germany a leading science and technology company, and SpringWorks Therapeutics, Inc a Stamford, Connecticut-based commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced the companies have entered into a definitive agreement for Merck KGaA, Darmstadt, Germany, to acquire SpringWorks. The purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion ((E)3.0 billion) based on SpringWorks' cash balance as of December 31, 2024, and a premium of 26% to SpringWorks' unaffected 20-day volume-weighted average price of $37.38 on February 7, 2025, the day prior to the first market speculation of a potential transaction between Merck KGaA, Darmstadt, Germany, and SpringWorks. The transaction has been unanimously approved, by all those in attendance, by both the Merck KGaA, Darmstadt, Germany, and SpringWorks Boards of Directors and is expected to close in the second half of 2025, subject to satisfaction of customary closing conditions, including approval of SpringWorks' shareholders and receipt of required regulatory approvals.